CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Corcept Reports Positive Results From Phase 2 Bella Trial Of Lifyorli® Combined With NAB-Paclitaxel And Bevacizumab In Patients With Platinum-Resistant Ovarian Cancer

By Reuters News

Oct 26 (Reuters) - Corcept Therapeutics Incorporated CORT.O:

  • CORCEPT REPORTS POSITIVE RESULTS FROM PHASE 2 BELLA TRIAL OF LIFYORLI® COMBINED WITH NAB-PACLITAXEL AND BEVACIZUMAB IN PATIENTS WITH PLATINUM-RESISTANT OVARIAN CANCER

  • CORCEPT THERAPEUTICS INCORPORATED - 88% OF PATIENTS ALIVE AT 6-MONTH OS TIMEPOINT IN BELLA TRIAL

  • CORCEPT THERAPEUTICS INCORPORATED - NO NEW SAFETY SIGNALS IDENTIFIED IN BELLA TRIAL FOR LIFYORLI COMBINATION

  • CORCEPT THERAPEUTICS INCORPORATED - MEDIAN PFS OF 7.2 MONTHS FOR LIFYORLI PLUS NAB-PACLITAXEL AND BEVACIZUMAB IN BELLA

Further company coverage: CORT.O

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk